Kangpu Bio successfully completes Phase I clinical study of KPG-818 in healthy subjects in the United States
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, Kangpu Bio
Pharmaceutical(http://Technology (Shanghai) LimitedCompany
(http://("Kangpu Biopharmaceuticals") announced that the company has successfully completed its Class I creationnew drug(http://KPG-818 in theHealth(http://subjects in the Phase I clinical studyThis randomized, double-blind, placebo-controlled clinicaltrial(http:// , the primary purpose is to assess the safety, tolerance and pharmacokinetics of KPG-818 in healthy subjects A total of 40 healthy subjects in the trial took part in five oral single-dose increment (SAD) cohorts (2, 5, 10, 20, 30 mg), each of which included 8 subjects, of whom 6 were given the drug and 2 were given a placebo The data showed that KPG-818 was absorbed more quickly in healthy subjects, with a half-life in the 5 dose groups in the 11-24 h range, and both AUC and Cmax had a good linear dependency with the dose of administration Safety this clinical trial has been used for the primary purpose of the study, with no serious adverse reaction events (SAEs) and no maximum tolerable dose The KPG-818 showed good safety and tolerance in the 30 mg dose range
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
